… The Tarceva or Chemotherapy (TORCH) study Citation49 is a Phase III randomized,
multicenter trial based on a noninferiority survival comparison between an experimental strategy …

… a multicenter (17 centers in China), open-label, phase II, randomized controlled trial of erlotinib
… Patients received erlotinib 150 mg/d (neoadjuvant therapy, 42 days; adjuvant therapy, up …

… This multicenter, randomized, open-label phase II trial compared the objective response
rate (ORR) as defined by RECIST 1.0 in the erlotinib plus fulvestrant arm versus erlotinib alone …

… This is a phase II, multicenter, open-label study of … of erlotinib in patients experiencing
treatment failure with one to two prior regimens, 9 we conducted a phase II study of erlotinib in …

… This study is a multicenter, prospective, open-label, randomized, Phase 2 study that was
conducted at four medical centers in South Korea (ClinicalTrials.gov, no. NCT03126799). …

… This was a nonrandomized, nonblinded, multicenter phase II trial to investigate the efficacy
of erlotinib in patients with locally advanced, recurrent and/or metastatic carcinoma of the …

… or second‐line treatment were randomized to receive either pemetrexed or erlotinib. In total,
… of patients in the erlotinib arm had squamous cell histology, and treatment was third line in …

… multicenter, double-blind, placebo-controlled phase III trial evaluating the efficacy and safety
of onartuzumab plus erlotinib … when treated with a combination of onartuzumab and erlotinib…

… , multicenter, phase II double-blind, placebo controlled trial (NCT00554775). Multicenter …
Adverse events were recorded up to 28 days after finishing erlotinib treatment, and graded …

… WJOG14420L), was designed as a multicenter, randomized phase III clinical trial (Figure
1). The primary objective of the study is to evaluate the efficacy of the combination of erlotinib …